EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa

N Mcgarvey,K Imanak,T Carattini,B Ung,T.B Campbell,M Gitlin,P Patwardhan

doi:10.1016/j.jval.2023.03.464

EE162 Healthcare Resource Utilization and 2022 Cost Update of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel (IDE-CEL, BB2121) in KarMMa

N Mcgarvey, K Imanak + Show 5 more

https://doi.org/10.1016/j.jval.2023.03.464

Copy DOI

Journal: Value in Health

Publication Date: Jun 1, 2023

Affiliation: Bristol-Myers Squibb (United States)

#Relapsed/Refractory Multiple Myeloma #Multiple Myeloma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

To estimate healthcare resource utilization (HCRU) and cost of cytokine release syndrome (CRS) and/or neurotoxicity (NT) management by grade among patients with relapsed/refractory multiple myeloma (RRMM) who received ide-cel, a BCMA-directed CAR T-cell therapy, in the KarMMa clinical trial (NCT03361748).

Full Text